Karen Thurman: “Yes. And we also correct a somewhat curious operation where they have actually kind of been involved or engaged with…”

“Yes. And we also correct a somewhat curious operation where they have actually kind of been involved or engaged with some generic companies where they actually have bought out or have actually delayed the generic drug coming to the market as well, and that is another area that we are trying to address in this piece of legislation. Let me ask the gentleman a question, because I do not have this information, and I wish the gentlewoman from Ohio (Mrs. Jones) was back here, because one of the things we did not talk about that I think is also very important, and certainly the gentleman and I have looked at this and the research, but this whole issue of the profits. Because one of the things that the American people are being told at this time and have been told, and by the way through rather large marketing of political statements to the tune of about $30 million in this last campaign to try to persuade people to believe, that there were things that ought not to happen in a benefit plan. And I quite frankly was offended in some of the tactics that were taken in scaring people as to what might have happened. But when we look at the profits and we start to do the breakdown, and I think Forbes came out with this, and I do not have it with me; but they were like four or five top parts, like profits or whatever.…”